CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?

Cancer metastasis and recurrence are the leading causes of cancer-related death. Tumor cells which leave the primary or secondary tumors and shed into the bloodstream are called circulating tumor cells (CTC). These cells are the key drivers of cancer dissemination to surrounding tissues and to dista...

Full description

Bibliographic Details
Main Authors: I. Kryvoshlyk, L. Skivka
Format: Article
Language:English
Published: National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry 2021-08-01
Series:Biotechnologia Acta
Subjects:
Online Access:http://biotechnology.kiev.ua/images/4_2021/kryvoshlyk_4_2021.pdf
_version_ 1797764655791210496
author I. Kryvoshlyk
L. Skivka
author_facet I. Kryvoshlyk
L. Skivka
author_sort I. Kryvoshlyk
collection DOAJ
description Cancer metastasis and recurrence are the leading causes of cancer-related death. Tumor cells which leave the primary or secondary tumors and shed into the bloodstream are called circulating tumor cells (CTC). These cells are the key drivers of cancer dissemination to surrounding tissues and to distant organs. The use of CTC in clinical practice necessitates the deep insight into their biology, as well as into their role in cancer evasion of immune surveillance, tumor resistance to chemo- radio- and immunotherapies and metastatic dormancy. Aim. The purpose of the work was to review the current knowledge on the CTC biology, as well as the prospects for their use for the diagnosis and targeted treatment of metastatic disease. Methods. The work proposed the integrative literature review using MEDLINE, Biological Abstracts and EMBASE databases. Results. This review summarizes and discusses historical milestones and current data concerning СTС biology, the main stages of their life cycle, their role in metastatic cascade, clinical prospects for their use as markers for the diagnosis and prognostication of the disease course, as well as targets for cancer treatment. Conclusions. Significant progress in the area of CTC biology and their use in cancer theranostics convincingly proved the attractiveness of these cells as targets for cancer prognosis and therapy. The effective use of liquid biopsy with quantitative and phenotypic characteristics of CTCs is impeded by the imperfection of the methodology for taking biological material and by the lack of reliable markers for assessing the metastatic potential of CTCs of various origins. The variety of mechanisms of tumor cells migration and invasion requires the development of complex therapeutic approaches for anti-metastatic therapy targeting CTCs. Efforts to address these key issues could help developing new and effective cancer treatment strategies.
first_indexed 2024-03-12T19:58:54Z
format Article
id doaj.art-6ea5f877bf924f7a8a4be1950fd9e9f7
institution Directory Open Access Journal
issn 2410-7751
2410-776X
language English
last_indexed 2024-03-12T19:58:54Z
publishDate 2021-08-01
publisher National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry
record_format Article
series Biotechnologia Acta
spelling doaj.art-6ea5f877bf924f7a8a4be1950fd9e9f72023-08-02T02:35:15ZengNational Academy of Sciences of Ukraine, Palladin Institute of BiochemistryBiotechnologia Acta2410-77512410-776X2021-08-01144527CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?I. Kryvoshlyk0L. Skivka1ESC “Institute of Biology and Medicine” Taras Shevchenko National University of Kyiv, UkraineESC “Institute of Biology and Medicine” Taras Shevchenko National University of Kyiv, UkraineCancer metastasis and recurrence are the leading causes of cancer-related death. Tumor cells which leave the primary or secondary tumors and shed into the bloodstream are called circulating tumor cells (CTC). These cells are the key drivers of cancer dissemination to surrounding tissues and to distant organs. The use of CTC in clinical practice necessitates the deep insight into their biology, as well as into their role in cancer evasion of immune surveillance, tumor resistance to chemo- radio- and immunotherapies and metastatic dormancy. Aim. The purpose of the work was to review the current knowledge on the CTC biology, as well as the prospects for their use for the diagnosis and targeted treatment of metastatic disease. Methods. The work proposed the integrative literature review using MEDLINE, Biological Abstracts and EMBASE databases. Results. This review summarizes and discusses historical milestones and current data concerning СTС biology, the main stages of their life cycle, their role in metastatic cascade, clinical prospects for their use as markers for the diagnosis and prognostication of the disease course, as well as targets for cancer treatment. Conclusions. Significant progress in the area of CTC biology and their use in cancer theranostics convincingly proved the attractiveness of these cells as targets for cancer prognosis and therapy. The effective use of liquid biopsy with quantitative and phenotypic characteristics of CTCs is impeded by the imperfection of the methodology for taking biological material and by the lack of reliable markers for assessing the metastatic potential of CTCs of various origins. The variety of mechanisms of tumor cells migration and invasion requires the development of complex therapeutic approaches for anti-metastatic therapy targeting CTCs. Efforts to address these key issues could help developing new and effective cancer treatment strategies.http://biotechnology.kiev.ua/images/4_2021/kryvoshlyk_4_2021.pdfcirculating tumor cellscirculating tumor microembolsmetastasisepithelial mesenchymal transitionminimal residual disease.
spellingShingle I. Kryvoshlyk
L. Skivka
CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
Biotechnologia Acta
circulating tumor cells
circulating tumor microembols
metastasis
epithelial mesenchymal transition
minimal residual disease.
title CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
title_full CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
title_fullStr CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
title_full_unstemmed CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
title_short CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
title_sort circulating tumor cells where we left off
topic circulating tumor cells
circulating tumor microembols
metastasis
epithelial mesenchymal transition
minimal residual disease.
url http://biotechnology.kiev.ua/images/4_2021/kryvoshlyk_4_2021.pdf
work_keys_str_mv AT ikryvoshlyk circulatingtumorcellswhereweleftoff
AT lskivka circulatingtumorcellswhereweleftoff